Skip to main content
. 2010 Aug 1;3(4):204–217. doi: 10.1593/tlo.09316

Figure 7.

Figure 7

MAb A4M VL CDR1 and 2 (L1, L2) are cytotoxic to B16F10-Nex2 melanoma cells (A) and induce DNA degradation in these cells (B). STD, 1 Kb Plus DNA Ladder. In human leukemia HL-60 cells, mAb A4M L2 peptide induces a dose- and time-dependent DNA degradation, which is blocked in HL-60 cells overexpressing antiapoptotic molecules (*P < .001, **P < .01) (C). Inhibition by mAb A4M CDRs L1 and L2 of HUVEC sprouting on Matrigel to form closed proangiogenic structures; *P < .001 relative to untreated control (-) (D). The mAb A4M cyclic-extended H3 inhibited mAb A4M binding to B16F10-Nex2 as shown by FACS (E) and by CL-ELISA (F). Negative control, cells incubated only with anti-IgM FITC. Positive control, mAb A4M alone (red).